First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. by CNBC Markets | January 5, 2026 7:10 pm | US Markets The drug’s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose.
